plant lover, cookie monster, shoe fiend
19379 stories
·
21 followers

A Chronically Ill Earth: COVID Organizing as a Model Climate Response in Los Angeles – Yale Global Health Review

1 Share

Read the whole story
sarcozona
13 hours ago
reply
Epiphyte City
Share this story
Delete

Kristina Mason (@kristina@ausglam.space)

1 Share
Read the whole story
sarcozona
13 hours ago
reply
Epiphyte City
Share this story
Delete

Canada pauses some counter tariffs against U.S.

1 Share
Read: 2 min

Canada has temporarily paused some counter tariffs against the United States, but Finance Minister Francois-Philippe Champagne on Sunday pushed back against claims they have all been quietly lifted.

This came as Prime Minister Mark Carney and U.S. Vice President JD Vance discussed trade in Rome after they attended the inauguration mass at the Vatican for Pope Leo XIV.

According to a readout from Carney’s office, they spoke about “immediate trade pressures and the need to build a new economic and security relationship.”

Vance in a brief statement called it “a casual meeting” about their two nations’ shared interests and goals, “including fair trade policies.”

Carney had slapped counter tariffs on billions of dollars of imports from the United States in response to U.S. tariffs on Canadian goods.

During the election campaign, automakers were offered a reprieve, provided they maintained production and investment in Canada.

This was outlined on May 7 in the Canada Gazette along with a pause on tariffs on products used in food and beverage processing and packaging, health, manufacturing, national security and public safety.

The moves went mostly unnoticed until Oxford Economics said in a report this week that the exemptions covered so many categories of products that the tariffs rate against the United States was effectively dropped to “nearly zero.”

Opposition leader Pierre Poilievre pounced on the claim, cited in the media, to accuse Carney of having “quietly dropped retaliatory tariffs to ‘nearly zero’ without telling anyone.”

Champagne called those assertions “falsehoods.”

“To retaliate against U.S. tariffs, Canada launched largest-ever response — including [US]$60B of tariffs on end-use goods. 70 per cent of those tariffs are still in place,” he said on X.

Canada’s levies, his office said, were “calibrated to respond to the U.S. while limiting economic harm to Canada.”

Tariff relief was provided for six months to give some Canadian companies “more time to adjust their supply chains and become less dependent on U.S. suppliers,” Champagne spokesperson Audrey Milette said.

Canada continues to charge levies on roughly C$43 billion of U.S. goods, she added.

The nation of 41 million people sends three-quarters of its exports to the United States, and the latest jobs report shows tariffs imposed by Trump are already damaging the Canadian economy.

The U.S. president has slapped general tariffs of 25 per cent on Canada as well as sector-specific levies on autos, steel and aluminum, but he has suspended some of them pending negotiations.

The post Canada pauses some counter tariffs against U.S. appeared first on CANADIAN AFFAIRS.

Read the whole story
sarcozona
14 hours ago
reply
Epiphyte City
Share this story
Delete

If only Arxiv required researchers to sign at the top rather than the bottom of the page, none of this would’ve happened.

1 Share

The story

A reader who would like to remain anonymous writes:

A story of research fraud just broke that I’d like to bring your attention to, if you haven’t heard it already.

Last year, a first year phd student in economics named Aidan Toner-Rodgers gained headlines for his paper on AI boosting scientific discovery. Acemoglu calls the work “fantastic” and David Autor was “floored.” I’m sure Autor was floored again when it was discovered that the entire thing was fake.

Hey, that’s a funny line!

My correspondent continues:

It seems TR made up everything; there likely was never an experiment in the first place. He even registered a domain name to look like Corning, who then sent him a cease-and-desist. This blog post by a material scientist points out some of the obvious red flags, as does this twitter thread by a professor of materials chemistry. MIT sent out a press release. They’ve asked arxiv to take down the paper and TR is no longer a student at MIT.

It’s an incredible story, especially given how popular that paper was upon the release of the preprint. It received an R&R from QJE and slipped by Acemoglu and Autor. I’ve been happy to see that the story of the fraud seems to be receiving about as much attention as the paper itself did upon release, but still sad that this could happen in the first place.

Hopefully my next correspondence with you is about research and not whatever this is.

“Whatever this is,” indeed!

I was curious so I googled the usual suspects (*Aidan Toner-Rodgers gladwell*, *Aidan Toner-Rodgers freakonomics*, *Aidan Toner-Rodgers NPR*, etc.), and some fun things came up:

From a Freakonomics episode, Is San Francisco a Failed State? (And Other Questions You Shouldn’t Ask the Mayor):

There was just a study from a grad student at M.I.T. describing how researchers using A.I. were able to discover 44 percent more materials than a randomly assigned group that didn’t have access to the technology.

From NPR’s Planet Money:

One of the big questions in economics right now is which types of workers benefit from the use of AI and which ones don’t. As we’ve covered before in the Planet Money newsletter, some early studies on Generative AI have found that less skilled, lower-performing workers have benefited more than higher skilled, higher-performing workers.

For economists like MIT’s David Autor, these early studies have been exciting. . . . Another recent study by MIT economist Aidan Toner-Rodgers found something similar. It looked at what happened to the productivity of over a thousand scientists at an R&D lab of a large company after they got access to AI. Toner-Rodgers found that “while the bottom third of scientists see little benefit, the output of top researchers nearly doubles.” Again, AI benefits those who can figure out how to use it well, and, it suggests, that in many fields, top performers could become more top performing, thereby increasing inequality.

Tyler Cowen shared the abstract of the Toner-Rodgers papers and none of his commenters sniffed out the problems.

Given that the paper fooled the reporters at the Wall Street Journal and the commenters at Marginal Revolution, it shouldn’t be such a surprise that perennially-credulous outlets such as Freakonomics and NPR fell for it too.

A smooth-looking research article . . .

After doing that quick web search, I followed the second link above to read Toner-Rodgers’s article. It was very well-written: it reads like a real econ paper! No wonder Acemoglu and Autor got conned: the paper is smooth and professional in appearance, down to the footnote on the first page thanking 21 different people as well as “seminar participants at NBER Labor Studies and MIT Applied Micro Lunch for helpful comments.” I’m reminded of the Technical Note at the end of the zombies paper.

. . . with some weird references

The first thing that jumped out at me was this in the reference list:

Diamandis, Peter. 2020. “Materials Science: The Unsung Hero.”

That guy’s a notorious bullshitter–how did that reference get into an otherwise serious-looking paper?

Actually, a lot of the references in Toner-Rodgers’s paper are incomplete, with no publication information at all, just a pile of things pulled off the internet, for example:

Bostock, J. 2022. “A Confused Chemist’s Review of AlphaFold 2.”
Cotra, Ajeya. 2023. “Language models surprised us.”
Ramani, Arjun, and Zhengdong Wang. 2023. “Why Transformative Artificial Intelligence is Really, Really Hard to Achieve.” The Gradient.
Schulman, Carl. 2023. “Intelligence Explosion.”

In the words of the late Joe Biden, “C’mon, man.”

The paper also cites 6 articles by Acemoglu and 6 by Autor . . . ok, I guess that’s why they were “floored” and thought the work was “fantastic.” If only Toner-Rodgers had found his way to including 10 references for each of them, maybe he could’ve moved up to “bowled over” and “amazing.”

Seriously, though, setting aside the junk references, I don’t know that I would’ve noticed any problems with the paper had it been sent to me cold.

Suspiciously wide confidence intervals

The only obviously suspect bits are Figures A.2 and A.3:

The intervals look too wide given how close the points are to the line. But my reaction in seeing something like this is that the model is probably misspecified in some way, or maybe the authors are reporting the results wrong. These graphs don’t scream “Fraud!”; they scream, “Someone is using statistical methods beyond his competence” (as with the multilevel model discussed here).

Funny p-values

Oh, yeah, there’s also Table A1:

Something funny about that first column, no? The estimate is 0.195, the standard error is 0.105, and it’s listed as significant at the 1% level. But 0.195/0.105 = 1.86, which, under the usual calculation, has a p-value of more than 5%.

And Table A3:

0.024/0.015 = 1.6, but a z-score of 1.6 is not significant at the 5% level.

And then these:

First, this looks wrong because with Poisson and negative binomial regressions, you’ll typically get similar point estimates but a wider standard error for the negative binomial. But here the point estimates are much different, and something seems wrong with the standard errors: the negative binomial has tiny standard errors. And again the p-values don’t match the numbers in the table. The estimates in the first two columns of Table A8 are a stunning (one might say, suspicious) 10+ standard errors from zero, but they’re starred as not reaching the 1% level of significance.

It’s kind of amazing for someone to have put so much effort into (allegedly) faking an entire study and then get sloppy at that last bit. Maybe he should’ve faked all the raw data so as to ensure internal consistency of his results. I kinda wonder where all these numbers came from. Maybe he used a chatbot to produce them? It would be kind of exhausting to construct them all from scratch.

That all said, had I been a reviewer I might have pointed out these anomalies, and then the numbers could’ve been cleaned up in the revision process and I’d have been none the wiser.

How did they spot the fraud?

OK, so my next question is, who figured out the paper was a fake, and how did they figure it out? From the Wall Street Journal article:

[Acemoglu and Autor] said they were approached in January by a computer scientist with experience in materials science who questioned how the technology worked, and how a lab that he wasn’t aware of had experienced gains in innovation.

Credit to Acemoglu and Autor for accepting this and not trying to shoot the messenger. Also credit to MIT, which did better than Columbia, UCB, and USC in handling research misconduct. I guess it’s easier to discipline a misbehaving student than a misbehaving professor. In any case, as an MIT alum, I appreciate their statement, “Research integrity at MIT is paramount – it lies at the heart of what we do and is central to MIT’s mission.” In this case, they talk the talk and they walk the walk.

To learn more I followed the link above to the material scientist’s blog post, which gives lots of details on suspicious aspects of the paper, various things that I wouldn’t have noticed–no surprise, given that the last time I published anything in material science was over 40 years ago! I recommend you read the whole thing (the material science post, not my old physics paper).

A story worthy of Borges

Above I asked, how is is that this student reportedly went to the trouble to make up an entire study, complete with a fake webpage, and complete and submit a long, professionally-written research paper based on fake study, and then fall down on his p-value calculations. Converting a z-score to a p-value, that’s the easiest thing in the world, no?

But after reading the report by the material scientist, I’m not so sure, as the p-values appear to be the least of the issues. If anything, Toner-Rodgers should’ve put less effort into faking the statistical summaries and more work into designing a more convincing fake study.

But it’s hard to design a convincing fake study. Fake things look fake. Reality is overdetermined. Remember that Borges story with a map that is on a one-to-one scale with reality? Anything else would be unrealistic. Similarly, if you want to fake a study, it should be coherent, and the only way to do that is to not just fake the tables but to fake the raw data, but then outsiders can check the raw data and find evidence for its construction, so really to be on the safe side you need to actually gather the data, which means you need to perform the study.

In short, the only way to produce a truly convincing fake experiment is . . . to do the experiment for real. But that would take a lot of work! (Also there’s a risk with real data that you might not find the effect you’re looking for, but modern methods of data analysis have enough researcher degrees of freedom that this shouldn’t be a problem.)

So, yeah, Toner-Rodgers showed real talent in writing a real-looking paper with lots of almost-real-looking tables and graphs–but perhaps his most impressive achievement was in “social engineering”: whatever it took for him to persuade Acemoglu, Autor, and others that he’d done a real study. You gotta be a stone-cold faker to pull that off.

A solution that should make everyone happy

The above-linked news article said that the author of this apparently-fraudulent paper is no longer at MIT. But this shouldn’t be a problem. When authors of fraudulent papers leave MIT, they usually can go to Duke, no? There must be a position in the business school for this guy. He has a great future ahead of him. Maybe some Ted talks?

Failing that, I’ve heard that UNR is doing a search for dean of engineering. “Artificial Intelligence, Scientific Discovery, and Product Innovation” sounds perfect for that, no? But really I think that Duke’s Fuqua School would be ideal, a place where he could be mentored by one of their senior faculty with very relevant expertise.

Read the whole story
sarcozona
15 hours ago
reply
Epiphyte City
Share this story
Delete

All-Cause Mortality and Life Expectancy by Birth Cohort Across US States | Public Health | JAMA Network Open | JAMA Network

1 Share
Key Points

Question  How did cohort life expectancies change by US state during the 20th century?

Findings  In this cohort study of 179 million deaths, cohort life expectancy in the South, especially among females, changed little for those born from 1900 to 2000. For several states in the West and Northeast, cohort life expectancy improved substantially, and Washington, DC, exhibited the greatest improvement.

Meaning  These findings suggest that understanding how mortality patterns vary by birth cohort within each state can inform decision-making around resource allocation and public health interventions.

Importance  Although overall US mortality rates declined from 1969 to 2020, they vary considerably by state and generation, especially when evaluated by birth cohort. Trends in mortality and life expectancy by birth cohort for US states and Washington, DC, have yet to be characterized.

Objective  To estimate cohort mortality trends for each state and Washington, DC, and quantify life expectancy at birth and 40 years of age and the rate of increase after 35 years of age.

Design, Setting, and Participants  In this cohort study, all-cause mortality rates by single years of age (0-119) and birth cohort (1900-2000) were estimated for each state in January 2025. Mortality data and population estimates were obtained from the National Center for Health Statistics, the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research website, and the Surveillance, Epidemiology, and End Results database for each state and Washington, DC, by single years of ages 0 to 84 and calendar years 1969 to 2020. An age-period-cohort model with constrained cubic splines for temporal effect estimates was used to estimate mortality from 1900 to 2000.

Main Outcomes and Measures  Life expectancy for each cohort from birth or 40 years of age was estimated by sex and state, along with doubling time for the death rate after 35 years of age.

Results  Analyses included 179 million deaths (77 million female and 102 million male). In the West and Northeast, cohort life expectancy improved from 1900 to 2000, but in some Southern states, it changed less than 3 years since 1900 in females and less than 2 years since 1950 in males. Washington, DC, had the lowest life expectancy in the 1900 birth cohort but a greater increase than the other states (from 61.1 to 72.8 years of age). After 35 years of age, the highest rate-doubling time in a state was 9.39 years in New York for females and 11.47 years for males in Florida. The shortest rate-doubling times were 7.96 years for females in Oklahoma and 8.95 years for males in Iowa.

Conclusions and Relevance  Cohort-specific patterns across states reveal wide disparities in mortality. Some states have experienced little or no improvements in life expectancy from the 1900 to 2000 birth cohorts. Understanding how mortality patterns vary by birth cohort within each state can inform decision-making around resource allocation and public health interventions.

A primary focus of the United Nations Sustainable Development Goals is the reduction of premature mortality in every country.1 Prior to some recent declines in US life expectancy,2 the US had experienced a considerable decrease in mortality rates and increasing life expectancy attributed to improvements in sanitation, tobacco control, health care, and prevention of cardiovascular disease, cancer, and other diseases.3 While overall mortality trends for the US have improved throughout the 20th century, there is considerable geographic variability by state. An analysis of life expectancy from 1959 to 2017 found differences widening between states, particularly after the 1980s and 1990s.4 These are undoubtedly shaped by state-level policies: states with progressive public health policies were more likely to experience increases in life expectancy than states without such policies.5 Spatial differences in mortality rates are also observed even at more granular levels by county.6,7

In the US, health policy is often established and implemented by states, and for many years, the effect of socioeconomic differences among the states has resulted in substantial differences in the health environment. This study reports on trends in mortality in each state that can help to understand the setting for health policies. Available data on state differences in mortality are usually analyzed cross-sectionally and not by birth cohort. While cross-sectional data allow for trend analysis by age group,8 each year includes different birth cohorts. Following cross-sections shifts the mixture of birth cohorts, so the generations are changing.9 For example, if following trends for people at 40 years of age, a 40-year-old individual born in 1950 would have different health experiences and mortality risks than one born in 1980. Herein we describe the differences in the period and cohort perspectives to better understand ways in which medical and public health policies can impact the health of different generations. The experience of a cohort early in life can shape exposures and risk factors that are carried forward as the group ages.10-12 Public health interventions often affect a cohort earlier in life, and the impact then follows them as they get older, as illustrated by a recent study of the potential impact of changing the minimum age for legal purchase of cigarettes.9 Summarizing mortality trends by birth cohort is thus more reflective of lived experiences of populations. This highlights the importance of the birth cohort perspective, a perspective that is largely absent from the usual summaries of state mortality data. This study aims to fill this gap by characterizing trends in mortality and life expectancy by birth cohort for US states and Washington, DC.

This study was approved by the Institutional Review Board of Yale University School of Medicine. This study used publicly available data collected by agencies of the US government, and no further contact with individuals or informed consent was required. The study complies with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies. In this cohort study, all-cause mortality rates by single years of age (0-119) and birth cohort (1900-2000) were estimated for each state in January 2025. Data on all-cause mortality for each state and Washington, DC, were obtained by single years of age (0-84) and calendar year (1969-2020) from the Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS), as shown in eFigure 1 in Supplement 1. For ages 1 to 84 years, the number of deaths for each year is available online for years 1969 to 1998.13 However, in subsequent years, online files suppress reporting of frequencies less than 10, resulting in biased estimates if these observations are dropped. For years 1999 to 2020, unrestricted vital statistics NCHS data were obtained with permission from NCHS.14 The number of deaths at younger than 1 year used the number of infant deaths reported by the CDC Wide-Ranging Online Data for Epidemiologic Research database.15-17 These files also do not report frequencies less than 10, so in some instances, sex- and state-specific frequencies were estimated by taking the difference between the total number of deaths and the number for the other sex, thus completing the data file. Population estimates were obtained from the Surveillance, Epidemiology, and End Results Program database.18

An age-period-cohort model was used to analyze temporal trends. Birth cohorts represented in the data begin in 1885 for individuals who were 84 years of age in 1969 through 2020 for those more recently born. For each state, a log-linear model was fitted to the mortality rate at age x and cohort t, similar to the equation of Lee and Hsieh,19

lnm(x,t) = μ + α(x) + γ(t) + π(t + x)

where μ is the intercept; α(x), the estimated effect of age x; γ(t), the estimated effect of cohort t; and π(t + x), the estimated effect of period. The number of deaths is assumed to have a distribution in which the variance is proportional to the mean, fitted using a generalized linear model, PROC GENMOD in SAS statistical software, version 9.4 (SAS Institute Inc). Estimated temporal effects were represented by constrained cubic splines in which the trends are constrained to be linear before the first and after the last knot.20 For age, a dummy variable was given for infants, 0 years of age, and knots were set at 2, 5, 10, 15, 25, and 35 years of age, which forces the estimated effect to be linear for 1 to 2 years of age or older than 35 years. The linear trend for the log rate after 35 years of age is the association specified by the Gompertz model.21 This analysis focuses on trends since birth and adults 40 years or older. For the cohort estimated effect, knots were placed in 1900, 1910, 1920, 1930, 1940, 1950, 1955, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 2000, and 2010. The period slope is set to zero, and knots are set at 1975, 1980, 1985, 1990, 1995, 2000, 2005, 2010, and 2015. Mortality in 2020 began to experience a surge caused by COVID-19, but the splines used to estimate mortality rates forced the period effect estimate to be linear after the last knot, 2015. This would temper the effect of the surge on these estimates and offer a better summary of long-term trends in mortality. Results from fitting this model provided mortality rate estimates for single years of age (0-119) and cohort (1885-2020) for each state. The rate estimates were constrained to be less than 1.

Both period and cohort life expectancies were calculated. Period life expectancy, the more commonly used method, uses the death rates for a given year and determines the life expectancy for a hypothetical population experiencing those rates.22 This was calculated from birth until 119 years of age for calendar years 1969 to 2020. For cohort life expectancies, the model estimates death rates for each age, 0 to 119 years, for cohorts born from 1900 to 2000. These rates were used to estimate the expected number of remaining years of life at any given age, which were reported from birth and from 40 years of age (eFigures 4-7 in Supplement 1) for each period and birth cohort.

The model used sets a linear trend for after 35 years of age with the slope β, which measures the rate at which the death rate increases with age.21 To more easily interpret this trend, time to double the mortality rate after 35 years of age is used, (log 2)/β. A steeper increase in the mortality rate yields shorter doubling times, which are shown for each state. Two-sided P < .05 indicated statistical significance. Two-sided 95% confidence limits are shown in eTables 1 and 2 in Supplement 1.

Neither race nor ethnicity is reported herein to maximize precision for estimates in all states. We report biological factors and refer to sex. No patients were generated from this work and permission to use these data was obtained from the National Center for Health Statistics.

Analyses used 179 million deaths (77 million female and 102 million male) in the US. Model estimates of death rates showed strong agreement with observed estimates in each state, as reported for California in eFigure 2 in Supplement 1. A comparison of typical differences in trend among states is demonstrated for Washington, DC, New York, and Oklahoma in eFigure 3 in Supplement 1.

Figure 1 and Figure 2 show the period life expectancy at birth in each state for years 1969, 1995, and 2020, ranked from highest to lowest in 2020. For females, states in the West and Northeast tended to have the highest life expectancy and states in the South the lowest (Figure 1). Hawaii had the highest life expectancy (84.5 years in 2020), and Arkansas (76.6 years in 2020), Alabama (76.4 years in 2020), Kentucky (76.4 years in 2020), West Virginia (75.9 years in 2020), and Mississippi (75.6 years in 2020) had the lowest. States with the lowest life expectancy also showed less change than other states, especially after 1995. Washington, DC, had the greatest change, increasing life expectancy from 70.4 to 80.2 years. Males showed an increase in life expectancy for each state, although the change was smaller after 1995 for states with the lowest life expectancy in 2020: Arkansas (69.8 to 70.9 years), Tennessee (69.7 to 70.7 years), Kentucky (70.1 to 70.6 years), Louisiana (68.7 to 70.3 years), Alabama (69.1 to 70.1 years), West Virginia (70.1 to 70.1 years), and Mississippi (68.0 to 68.9 years) (Figure 2). Washington, DC, showed an even greater increase in life expectancy from 62.7 to 72.8 years of age. Rankings differed somewhat by sex, though the same states tended to appear in the lowest ranking. Similar results for life expectancy at 40 years of age are shown in eFigures 4 and 5 in Supplement 1.

Figure 3 and Figure 4 show cohort life expectancy at birth by state and cohort (1900, 1950, and 2000), ordered from highest to lowest in 2000. Life expectancies were generally higher for females than males and increased with cohort. However, in many Southern states, there was little change from 1900 to 2000 in females, but higher life expectancies and greater improvement occurred in the Pacific and Northeast (Figure 3). For many of these states, males showed some improvement up to 1950, which decreased to less than 2 years thereafter (Figure 4). The greatest observed change was for Washington, DC, which had the lowest cohort life expectancies in the 1900 cohort (63.9 years for females and 48.7 years for males) and the highest in 2000 for females (93.0 years) and the third highest for males (86.5 years). Life expectancies in 2000 were only slightly different than that of Washington, DC, in New York (91.9 years for females and 87.8 years for males) and California (91.3 years for females and 86.8 years for males). For both sexes, the 8 states with the lowest life expectancy are in the South (Oklahoma, Arkansas, Kentucky, Tennessee, Louisiana, Alabama, West Virginia, and Mississippi). Life expectancy in some of these states changed less than 3 years from 1900 to 2000 in females and less than 2 years from 1950 to 2000 in males. Life expectancies at 40 years of age by cohort are shown in eFigures 6 and 7 in Supplement 1.

The doubling times after 35 years of age, showing the rate of increase in mortality, a measure of the rate that a cohort is aging, are shown in the Table. These are shown with confidence limits in eTables 1 and 2 in Supplement 1. In each state, the mortality doubling time is higher for females than for males, although there is considerable variation by state. Washington, DC, is an outlier with doubling times of 12.27 for females and 15.64 years for males. Other states had rate doubling times of 7.96 to 9.39 for females and 8.95 to 11.47 for males. Pearson correlation between the doubling times for males and females in each state was 0.96 overall, but only slightly less, 0.88, if Washington, DC, was dropped. Doubling times were also correlated with life expectancy in 2000 (r = 0.49 in females [P < .001] and r = 0.28 in males [P = .046]). States in the Midwest tend to have faster doubling times for both females and males. For females, Oklahoma has the shortest doubling time, and those in Iowa and Kansas were also quite short. New York and Florida had relatively higher doubling times. Estimated age-specific mortality rates by state, sex, and cohort, along with additional figures showing life expectancy, are available on a data repository website.24

This cohort study is the first, to our knowledge, to provide a comprehensive history of mortality trends across US states by birth cohort. We improve on existing state-specific mortality data that have focused primarily on trends by period (calendar year). The Gompertz model21 for cohort mortality trend after 35 years of age aligns well with the mortality data for each state and Washington, DC. Although some cohort-specific trends can be gleaned from observational data, the fitted models can be used to extrapolate mortality beyond the range of age and cohort where data are available, providing estimates for 85 years and older and cohorts born early in the 20th century. This reveals mortality changes across the life course between different generations across US states. We use a model for the estimated age effect that works well for the available data, but these estimates extend to 2119 for the 2000 cohort. One should use caution if relying on these estimates for prediction purposes, but these data provide a useful starting point for estimating the expected potential effects of health intervention strategies affecting cohorts. Nevertheless, uncertainty exists for these estimates, both from random error and future events and changes to health care. The rate of increase in adult mortality rate is characterized by the time to double the mortality rate after 35 years of age. Longer time for mortality to double suggests slower rates of increase in the death rate for a population. Mortality doubling time is consistently higher for males, indicating that their rate of increase in mortality with age is slower than that for females. However, the mortality rate itself remains higher for males than females over the entire life span. This pattern of lower but more rapidly increasing mortality by age in females vs males has also been found in comparisons of mortality by birth cohort and gender between different countries.11 The mortality rate doubling times vary considerably across states, with those for Washington, DC, being considerably higher than for the other states.

Variation in change in cohort life expectancy is large; for example, female cohort life expectancy in New York increased 20 years from 1900 to 2000 cohorts, but Oklahoma decreased by 0.7 years. Reasons for variation in the cohort life expectancies can be complex and include health behaviors such as cigarette smoking, drug use, environmental safety, social interactions, vaccination, and access to effective health care. In addition, infection and other causes of inflammation have been suggested as reasons for mortality trends.12 These can have differential effects on specific causes of death that affect the overall burden of disease in a state.25,26 Prior studies have considered mortality and disease from the perspective of calendar year or period but have not provided summaries for individuals by birth cohorts. The cohort trends can assess the outcomes of policy changes that have more impact on individuals of a particular age and impact health thereafter. Spatial trends can also occur at a finer geographic level, such as counties or towns, due to more localized factors affecting health.6,7 However, for small regions, the population size can make it difficult to estimate cohort life expectancy.

Persistent disparities in mortality rates reflect important state and regional differences in public policy, sociodemographic composition, rurality, and other social and behavioral norms that influence mortality outcomes.5 California was an early adopter of tobacco control policies, which influenced smoking and subsequent mortality trends. California implemented smoke-free workplace policies in 1995,27 which changed smoking behaviors and social norms for entire cohorts of young people born in the 1980s and 1990s who grew up surrounded by smoke-free environments, as well as generations of working-age adults who were prompted to quit. In contrast, Kentucky had essentially no such efforts to control cigarette smoking, resulting in higher cigarette use28 and, therefore, higher mortality compared with California. Similar patterns for smoking and mortality observed in Kentucky can be seen in West Virginia, Oklahoma, Arkansas, Tennessee, Louisiana, Mississippi, and Alabama. Lower socioeconomic status is associated with higher mortality risk; states that are socioeconomically advantaged in their demographic composition also appear to have improved mortality rates more quickly than other states. Many factors affect mortality, including policies related to labor, immigration, civil rights, and the environment.5

Washington, DC, has shown much greater change among cohorts born in the 20th century than the states, as seen in mortality rates, life expectancy, and time to double mortality after 35 years of age. However, unlike the 50 states, it is essentially an urban area, which often has better access to health care deand longer life expectancy than rural areas.29 In addition, its small size can make it sensitive to changes in the demographic mix of the population. Washington, DC, has a relatively small population compared with most states, so a relatively small number of migrating individuals may result in a relatively large change in its demographic distribution. This could reflect a pattern of gentrification as more affluent individuals, with better health care options, move into the nation’s capital.

Strengths and Limitations

This study is strengthened by detailed comprehensive historical mortality data for each state and application of a linear model between log-mortality and temporal factors. The analysis makes use of the age-period-cohort model to generate these rates, which agrees well with available data, but it has limitations that are well recognized.30 Although demographic changes and migration patterns by state are not explicitly accounted for in the analysis, the underlying data reflect those shifts in the population composition for each state. The results reveal solid agreement between model estimates and observed mortality rates where data are currently available. However, this does not ensure that this agreement would have held in earlier years (pre-1969) or will continue in future years (post-2020). Geographic disparities in COVID-19–related mortality and the policies that shaped them after 2020 were not considered. Future research could examine how state-specific migration patterns, demographic composition, and COVID-19–related experiences shape mortality trends for future cohorts.

In this cohort study of mortality by state in the US, both period and cohort life expectancy were estimated for males and females using an age-period-cohort model. From 1969 to 2020, period life expectancy increased, although there was greater improvement for some states in the West and Northeast and less for some states in the South. Some states in the West and Northeast showed increases in the cohort life expectancy greater than 30 years for those born in 2000 compared with 1900. However, in parts of the South, female cohort life expectancy increased by less than 2 years. For male cohorts in parts of the South, life expectancy increased from 1900 to 1950 but by less than 2 years after 1950.

State- or local-level decision-makers benefit from the availability of detailed mortality data that more accurately reflect their jurisdiction’s population. The birth cohort perspective is particularly important for capturing potential changes in mortality that would otherwise be masked in cross-sectional analyses. Understanding how these mortality patterns vary by birth cohort within each state can inform decision-making around resource allocation and public health interventions, especially those that may differentially affect birth cohorts. For example, policies directed at screening for disease or access to exposure affecting health are often directed at age groups, and the effect of these policies then follows cohorts as they get older. States with more progressive public health policies have generally fared better,5 and these are often more closely linked to cohort parameters. These mortality estimates can furthermore be used in simulation models to make projections about mortality trends in the future and how public policy intervention could alter those trajectories. Importantly, such data can facilitate surveillance of trends to determine whether state disparities are improving or worsening with more recent birth cohorts. If addressing geographic health disparities is indeed a nationwide priority, then this study contributes to the necessary data infrastructure for health equity progress.

Accepted for Publication: February 26, 2025.

Published: April 28, 2025. doi:10.1001/jamanetworkopen.2025.7695

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2025 Holford TR et al. JAMA Network Open.

Corresponding Author: Theodore R. Holford, PhD, Department of Biostatistics, Yale School of Public Health, 432 Humphrey St, New Haven, CT 06511 ([email protected]).

Author Contributions: Dr Holford had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Holford, Meza.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Holford, McKay, Tam.

Critical review of the manuscript for important intellectual content: Holford, Tam, Jeon, Meza.

Statistical analysis: Holford, McKay, Meza.

Obtained funding: Holford, Tam, Meza.

Administrative, technical, or material support: Holford, McKay.

Supervision: Holford.

Conflict of Interest Disclosures: Dr Tam reported receiving grant support from the National Institute on Drug Abuse and the National Cancer Institute (NCI) during the conduct of the study. Dr Meza reported receiving grant support from the National Institutes of Health (NIH) during the conduct of the study. No other disclosures were reported.

Funding/Support: This work was supported by grant U01CA253858 from the the NCI of the NIH.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 2.

1.

Norheim  OF, Jha  P, Admasu  K,  et al.  Avoiding 40% of the premature deaths in each country, 2010-30: review of national mortality trends to help quantify the UN sustainable development goal for health. 

 Lancet

. 2015;385(9964):239-252.

PubMedGoogle ScholarCrossref
2.

Xu  J, Murphy  SL, Kochanek  KD, Arias  E.  Mortality in the United States, 2021. 

 NCHS Data Brief

. 2022;(456):1-8.

PubMedGoogle Scholar
3.

Ma  J, Ward  EM, Siegel  RL, Jemal  A.  Temporal trends in mortality in the United States, 1969-2013. 

 JAMA

. 2015;314(16):1731-1739.

PubMedGoogle ScholarCrossref
4.

Woolf  SH, Schoomaker  H.  Life expectancy and mortality rates in the United States, 1959-2017. 

 JAMA

. 2019;322(20):1996-2016.

PubMedGoogle ScholarCrossref
5.

Montez  JK, Beckfield  J, Cooney  JK,  et al.  US State policies, politics, and life expectancy. 

 Milbank Q

. 2020;98(3):668-699.

PubMedGoogle ScholarCrossref
6.

Shiels  MS, Berrington de González  A, Best  AF,  et al.  Premature mortality from all causes and drug poisonings in the USA according to socioeconomic status and rurality: an analysis of death certificate data by county from 2000-15. 

 Lancet Public Health

. 2019;4(2):e97-e106.

PubMedGoogle ScholarCrossref
7.

Shiels  MS, Tatalovich  Z, Chen  Y,  et al.  Trends in mortality from drug poisonings, suicide, and alcohol-induced deaths in the United States from 2000 to 2017. 

 JAMA Netw Open

. 2020;3(9):e2016217.

PubMedGoogle Scholar
8.

Shiels  MS, Chernyavskiy  P, Anderson  WF,  et al.  Trends in premature mortality in the USA by sex, race, and ethnicity from 1999 to 2014: an analysis of death certificate data. 

 Lancet

. 2017;389(10073):1043-1054.

PubMedGoogle ScholarCrossref
9.

Tam  J, Crippen  A, Friedman  A,  et al.  US Tobacco 21 policies and potential mortality reductions by state. 

 JAMA Health Forum

. 2024;5(12):e244445.

PubMedGoogle Scholar
10.

Tango  T, Kurashina  S.  Age, period and cohort analysis of trends in mortality from major diseases in Japan, 1955 to 1979: peculiarity of the cohort born in the early Showa Era. 

 Stat Med

. 1987;6(6):709-726.

PubMedGoogle ScholarCrossref
11.

Meza  R, Pourbohloul  B, Brunham  RC.  Birth cohort patterns suggest that infant survival predicts adult mortality rates. 

 J Dev Orig Health Dis

. 2010;1(3):174-183.

PubMedGoogle ScholarCrossref
12.

Finch  CE, Crimmins  EM.  Inflammatory exposure and historical changes in human life-spans. 

 Science

. 2004;305(5691):1736-1739.

PubMedGoogle ScholarCrossref
21.

Gompertz  B.  On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. 

 Philos Trans R Soc Lond

. 1825;115:513-583.

Google Scholar
22.

Chiang  CL.  The Life Table and Its Applications. Krieger Publishing Co; 1984.

25.

GBD 2021 US Burden of Disease Collaborators.  The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. 

 Lancet

. 2024;404(10469):2314-2340. doi:

10.1016/S0140-6736(24)01446-6



PubMedGoogle ScholarCrossref
27.

Sheridan  P, Trinidad  D, McMenamin  S, Pierce  JP, Benmarhnia  T.  Evaluating the impact of the California 1995 smoke-free workplace law on population smoking prevalence using a synthetic control method. 

 Prev Med Rep

. 2020;19:101164. doi:

10.1016/j.pmedr.2020.101164



PubMedGoogle ScholarCrossref
Read the whole story
sarcozona
15 hours ago
reply
Epiphyte City
Share this story
Delete

Are seed oils healthy? The research is unclear | STAT

1 Comment

For decades, mainstream nutrition guidelines have recommended that Americans replace animal fats like butter or lard with polyunsaturated fats, especially seed oils such as soybean, corn, and sunflower oils. These oils are rich in omega-6 fatty acids and now make up a significant portion of the fat consumed in the standard American diet.

But recently, the conversation has shifted. Some high-profile figures, including Health and Human Services Secretary Robert F. Kennedy Jr., have claimed that seed oils are harmful and promote inflammation and chronic disease. Critics of seed oils are often accused of spreading fear or misinformation — and sometimes those concerns are justified. But here’s the uncomfortable truth: The scientific community has not definitively determined the health effects of high seed oil consumption. And the current evidence is not as conclusive or unidirectional as many assume.

I say this as a researcher who has been studying diet, genetics, and chronic disease for more than 10 years. When I first entered this field, I assumed the science around dietary fats was largely settled. So I was surprised to see how much disagreement still exists surrounding seed oils not just in the public discourse, but among scientists themselves.

Several years ago, I attended a large international nutrition science conference where one session in particular caught my attention. The session was titled: “Why Omega-6 Fatty Acids Are Good for Health.” The wording struck me as odd. Omega-6 fatty acids are the main component of seed oils. The session wasn’t framed as a question “Are seed oils good or bad?” but instead as a defense of their health benefits. That assumption felt premature. We were gathering as scientists to explore evidence and challenge accepted thinking, yet the session title suggested preconclusion. When the presentations began, the speakers largely focused on how omega-6 fatty acids reduce LDL (“bad”) cholesterol, a commonly accepted surrogate marker for heart disease risk. What the session didn’t address in depth was whether long-term, high consumption of seed oils truly results in better health outcomes, or whether the mechanistic link between omega-6 levels and disease risk might be more complex.

This conference experience was just one example, but it reflected a broader tendency in the nutrition science community to simplify public health recommendations. To be clear: I am not saying that seed oils are “bad.” I’m saying we don’t know. That’s why I don’t eat food made with seed oils myself, as I’m not sure what the causal effect is. It is my personal choice, you may agree or not agree. As it stands now, the only conclusions we can draw from the scientific evidence is to be cautious, especially when we are talking about mass consumption of a food component that was virtually absent from the human diet 100 years ago.

The truth is, we don’t fully understand what the causal effect of omega-6 fatty acids is, which dominate most seed oils, on disease risk.

While traditional observational studies often link omega-6 intake to better cardiovascular outcomes, these studies come with well-known limitations: People who consume more seed oils may also engage in other healthy behaviors that confound the results. History offers many cases — such as vitamins A, D, and E — in which repeated observational benefits were later contradicted by randomized controlled trials (RCTs), the gold standard for establishing causality. For example, evidence from observational studies show that dietary vitamin A intake was related to lower cardiovascular risk, but a large RCT in 11,036 participants showed no benefit.

In the case of omega-6 fatty acids, both RCTs and Mendelian randomization (MR) studies — a genetic epidemiology method used to infer causality — paint a more mixed picture. Evidence from MR suggests that higher endogenous omega-6 levels have no benefit on heart disease. Of course, MR is not perfect, either. Every study comes with limitations. However, the MR evidence echoes findings from RCTs. For example, the Minnesota Coronary Survey, a large RCT conducted in 1968-1973 with over 9,000 participants, showed that cholesterol lowering by replacement of saturated fat with vegetable oil rich in linoleic acid did not lower the risk of coronary heart disease. Meta-analyzing this study with other clinical trials also showed no benefit. Taken together, these findings suggest that the case for seed oils as unequivocally “heart-healthy” is not closed.

Seed oils are everywhere in the modern food supply. Fast food, packaged snacks, salad dressings, and even so-called “healthy” foods often rely on soybean or corn oil as the primary fat. According to a study using data from USDA, Americans get around 8% of their daily calories from linoleic acid, the primary omega-6 fat in seed oils, a massive jump from early 20th-century levels. Yet we’ve only scratched the surface in understanding what sustained intake at these levels means for long-term health.

The scientific community should be honest about this uncertainty. It’s OK to say: “We don’t yet have all the answers.” Doing so doesn’t confuse the public; it respects them. It signals that we’re still asking questions and are open to new evidence, even if it challenges longstanding beliefs.

Until we know more, we should be cautious about making sweeping recommendations. In the meantime, the best advice may be this: favor balance over extremes. That means not fearing every bite of croissant, but also not assuming that loading every meal with seed oils is a surefire path to good health.

The seed oil debate doesn’t need more hype — it needs more humility. And more science.

Jane Zhao, a Takemi fellow at Harvard and assistant professor at the University of Hong Kong, has more than 10 years’ experience researching the causal effects of dietary factors and medications on chronic diseases.

Read the whole story
sarcozona
15 hours ago
reply
Unjustified confidence destroys credibility
Epiphyte City
Share this story
Delete
Next Page of Stories